Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Berceanu, Ana  [Clear All Filters]
2023
Xhaard A, Xhaard C, Rubio M-T, Berceanu A, Botella-Garcia C, Coman T, Tavernier E, Labussière-Wallet H, Chevallier P, Legrand F, et al. A 16-month-long experience of COVID-19 in allogeneic haematopoietic stem cell transplantation recipients: An SFGM-TC multicentre cohort study. Br J Haematol. 2023.
Peterlin P, Le Bris Y, Turlure P, Chevallier P, Ménard A, Gourin M-P, Dumas P-Y, Thépot S, Berceanu A, Park S, et al. CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2023.
Michel C, Robin M, Morisset S, Blaise D, Maertens J, Chevalier P, Castilla-Llorente C, Forcade E, Ceballos P, Yakoug-Agha I, et al. Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS. Bone Marrow Transplant. 2023.
Rossi M, Szepetowski S, Yakouben K, Paillard C, Sirvent A, Castelle M, Pegon C, Piguet C, Grain A, Angoso M, et al. Recent results of hematopoietic stem cell transplantation for thalassemia with busulfan-based conditioning regimen in France: improved thalassemia free survival despite frequent mixed chimerism. A retrospective study from the Francophone Society of Stem C. Bone Marrow Transplant. 2023.
Gavriilaki E, Sakellari I, Labopin M, Bornhäuser M, Hamladji R-M, Casper J, Edinger M, Žák P, Yakoub-Agha I, Ciceri F, et al. Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute . Bone Marrow Transplant. 2023.
Saraceni F, Labopin M, Raiola AM, Blaise D, Reményi P, Sorà F, Pavlu J, Bramanti S, Busca A, Berceanu A, et al. Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT. Hemasphere. 2023;7(10):e952.
2022
Trad R, Warda W, Alcazer V, da Rocha MNeto, Berceanu A, Nicod C, Haderbache R, Roussel X, Desbrosses Y, Daguindau E, et al. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J Immunother Cancer. 2022;10(7).
Caillet A, Bellanger A-P, Navellou JChristophe, Daguindau E, Rocchi S, Scherer E, Berceanu A, Millon L. Refractory invasive pulmonary aspergillosis due to Aspergillus flavus detected with the combination of two in-house Aspergillus qPCR. J Mycol Med. 2022;33(1):101350.
Swoboda R, Labopin M, Giebel S, Schroeder T, Kröger N, Arat M, Savani B, Spyridonidis A, Hamladji R-M, Potter V, et al. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par. Bone Marrow Transplant. 2022.
2021
Jullien M, Orvain C, Berceanu A, Couturier M-A, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, et al. Early Post-Transplant Serum Ferritin Levels Predict Survivals in Recipients of Haploidentical Stem Cell Transplantation Using PTCY as GVHD Prophylaxis. Transplant Cell Ther. 2021.
Jullien M, Orvain C, Berceanu A, Couturier M-A, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, et al. Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide. Cancer Med. 2021.
2020
Chevallier P, Berceanu A, Peterlin P, Garnier A, Le Bourgeois A, Imbert B-M, Daguindau E, Mahe B, Dubruille V, Blin N, et al. Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta Oncol. 2020:1-9.
2019
Fayard A, Daguenet E, Blaise D, Chevallier P, Labussière H, Berceanu A, Yakoub-Agha I, Socié G, Charbonnier A, Suarez F, et al. Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell. Bone Marrow Transplant. 2019.